New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:10 EDTWAG, DDAIF, PFE, BMYOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: U.S. businesses took on new office space at a sluggish pace in Q4, as employers remained cautious about adding jobs, the Wall Street Journal reports...This week Walgreen Co. (WAG) executives will outline what's ahead for the drugstore chain in 2013, with some analysts saying a busy flu season and firmer prescription orders could help the company outperform its rivals, the Wall Street Journal reports...REUTERS: Major U.S. technology companies could miss estimates for Q4 earnings as "fiscal cliff" concerns likely led some corporate clients to tighten their belts last month and hold off on spending all of their 2012 IT budgets, Reuters reports...The U.S. dominates the list of places that global commercial real estate investors would prefer to invest their money this year, while China has lost some luster and Turkey has drawn more interest, according to an annual survey by the Association of Foreign Investors in Real Estate, Reuters reports...BLOOMBERG: China Investment Corp. may acquire a holding of 4% to 10% in Daimler AG (DDAIF), according to the Chinese newspaper People’s Daily which reported the country’s sovereign-wealth fund may buy a stake in the luxury car maker, Bloomberg reports...The return of $10B-plus drug deals may be here as pharmaceutical companies including Pfizer (PFE) and Bristol-Myers Squibb (BMY) may be ready to start buying again. Five of the largest U.S. drug makers had more than $70B in cash, near cash and short-term investments at the end of the Q3, Bloomberg reports.
News For WAG;DDAIF;PFE;BMY From The Last 14 Days
Check below for free stories on WAG;DDAIF;PFE;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 22, 2014
07:24 EDTDDAIFMercedes invests in training, distribution to catch up in China, WSJ says
Daimler's (DDAIF) Mercedes-Benz unit is investing in China to build its biggest training facility in the world for car dealers and to add 100 new distribution outlets as it works to close the gap in the country with German automaking rivals BMW (BAMXY) and Audi, reported The Wall Street Journal. Reference Link
06:24 EDTDDAIFMercedes aims to outpace China luxury car sales growth, Bloomberg says
Daimler’s Mercedes-Benz foresees outpacing the growth in industry sales of luxury cars in China this year, after merging two rivaling sales networks and adding new models including its new C-class sedan, according to Bloomberg, citing comments from the head of Mercedes-Benz in China Nicholas Speeks. Speeks said the car manufacturer is confident that deliveries will exceed 300K units next year with sales this year reaching close to 250K units. Reference Link
July 21, 2014
06:43 EDTBMYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 18, 2014
10:03 EDTDDAIFOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:21 EDTWAGCTW Investment asks SEC to probe Walgreen's meetings, NY Post says
CTW Investment Group has asked the SEC to investigate private meetings that top Walgreen (WAG) executives held with investors to reincorporate overseas for tax reasons, reports the New york Post. The pension advisor is raising questions about whether Walgreen's meetings with Goldman Sachs (GS), Jana Partners, Och-Ziff and Corvex broke fair disclosure rules. Reference Link
04:59 EDTDDAIFDaimler AG downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
July 17, 2014
08:27 EDTDDAIFMercedes-Benz issues recall due to air bag assembly error
Subscribe for More Information
08:08 EDTPFE, BMYBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
July 16, 2014
11:42 EDTDDAIFDaimler to debut new Smart 4, 2 seat vehicles, Automotive News says
Subscribe for More Information
10:36 EDTPFETreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
07:59 EDTPFETreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
06:27 EDTWAGWalgreen could relocate to Switzerland if it buys out Alliance Boots, WSJ says
Subscribe for More Information
06:26 EDTBMYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTBMYPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
07:35 EDTBMYPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 14, 2014
06:06 EDTWAGWalgreen implied volatility of 35 at upper end of index mean range
July 11, 2014
06:03 EDTWAGWalgreen implied volatility of 34 at upper end of index mean range
Subscribe for More Information
July 10, 2014
12:43 EDTBMYBristol-Myers announces plans for Q3 submission of Opdivo BLA
Bristol-Myers Squibb announced earlier that, following discussions with the FDA, the company is planning a Q3 submission of a Biologics Licensing Application for Opdivo for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S. “We continue to collaborate closely with the FDA on Opdivo and the planned submission in advanced melanoma represents an important step forward in our company’s commitment to deliver innovative treatment options for patients with cancer,” said Michael Giordano, MD, Head of Oncology Development, Bristol-Myers Squibb. The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine or carboplatin/paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy and, if BRAF-mutation positive, a BRAF inhibitor regimen. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trade name for nivolumab.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use